Investing.com loses its position as a candidate for the treatment of Pluristem Tanks Covid
[ad_1]
Author: Dhirendra Tripathi
Investing.com – Pluristem Stock (NASDAQ 🙂 fell more than 18% on Monday when the company’s Covid-19-related serious effects candidate failed to meet the required points in a Phase II study.
The aim of the treatment is to use intravenous injections to administer cells called Pluristem, called PLX-PAD, to treat acute respiratory failure syndrome associated with viral infection.
Treatment did not statistically improve the number of days without ventilators for patients during the 28-day study, the company said.
The study is based on 89 patients enrolled in two Phase II studies: one in the US and the other in a combined study in Europe and Israel, the company’s home country.
The company had previously projected a total of 180 patients in both studies, but reduced the number in response to changes in Covid-19’s standard of care. This change led to a reduction in the statistical capacity of studies.
Pluristem said that with the emergence of a new omicron-shaped threat, it wants to explore the possibilities based on the efficiency trends obtained from recent research.
Fusion Media or anyone involved with Fusion Media will not be held liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained on this website. Please be informed that one of the most risky forms of investment possible is the full information on the risks and costs associated with trading in the financial markets.
[ad_2]
Source link
